Annals of Oncology Current Issue
订阅

最新

1. 166P Insights in the mode of action of a T cell bispecific antibody in tumour bearing mice Giusti A, Sam J, Karagianni M, et al.
2. 78P A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM) Tagliamento M, Bironzo P, De Luca E, et al.
3. 77P The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients Jo H, Yoshida T, Yagishita S, et al.
4. 12P The expression of PD-1 alone by T cells is associated with cell activation while the co-expression of TIM-3 indicates exhausted subsets both in peripheral blood and bone marrow of multiple myeloma patients Batorov E, Sergeevicheva V, Aristova T, et al.
5. 151P Investigation of the mechanism of action of anti-PD-1 treatment by systematic depletion of different immune cell populations in syngeneic models Bourre L, Jin Y, Muntel J, et al.
6. 6P Prognostic significance of tumour-infiltrating lymphocytes on survival outcomes of patients with resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis Tan H, Catedral L, San Juan M.
7. 54P Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors Vuagnat P, Auclin E, Mezquita L, et al.
8. LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study Herbst R, de Marinis F, Giaccone G, et al.
9. 35O Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer Lin Y, Chen S, Zhong S, et al.
10. 161P Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC Soliman R, Youness R, El-Shazly M, et al.
11. 47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice Drakaki A, Luhn P, Wakelee H, et al.
12. 48P A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients Choi J.
13. 162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours Marabelle A, Cassier P, Delord J, et al.
14. 49P Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study Bravo P, Vss B, Baldini C, et al.
15. 135P Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy Bhagat M, Warren S, Elliott N, et al.
16. LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis Paz-Ares L, Ciuleanu T, Yu X, et al.
17. 7P Multispectral immunofluorescence and computational imaging analysis define the prognostic role of T-cell infiltrates in gastric cancer Challoner B, von Loga K, Woolston A, et al.
18. 160P Novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas Pilanc-kudlek P, Cyranowski S, Wojnicki K, et al.
19. 116P Development of advanced human immune system mouse models for pre-clinical research in immuno-oncology Mossu A, Tschumi B.
20. 130O Association of long non-coding RNA biomarkers with clinically immune subtype and prediction of immunotherapy in patients with cancer Yu Y, Zhang W, Li A, et al.
21. 96P Clearance of HPV anal premalignant lesions and modulation of systemic immune responses to HPV oncogenes with low dose pomalidomide Polizzotto M, Van Bockel D, Law C, et al.
22. 52P Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019 Ghisoni E, Marandino L, Valabrega G, et al.
23. 123P Patient-Derived Explant Cultures (PDECs) as a model system for immuno-oncology studies Turpin R, Munne P, Suleymanova I, et al.
24. LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC Gadgeel S, Rodriguez-Abreu D, Felip E, et al.
25. 137P Comparative analysis of the immune microenvironment in histological subtypes of lung and breast cancer using a tissue microarray (TMA) comprising invasive margin (IM) and tumour centre (TC) Cumberbatch M, Memeo L, Womack C, et al.
26. 45P 5-AZA treatment induces cytotoxicity and in vitro expression of immunogenic NY-ESO-1 antigen in non-small lung cancer cell NCI-H1975 Inchakalody V, Taleb S, Sherif S, et al.
27. 39P TCR engaging antigen-scaffolds for targeted expansion of functionally improved T cells for adoptive cell therapy Kladis G, Mindahl V, Tamhane T, et al.
28. 147P A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma Desai K, Ragulan C, Lawrence P, et al.
29. 102P Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study Merino L, Cruz J, Alonso J, et al.
30. 159P Supportive roles of microglia in breast cancer brain metastases Kaminska B, Wojnicki K, Kochalska A, et al.
31. 38P Obtaining tumour-specific T cells in a mouse melanoma model Yuzhakova D, Izosimova A, Barbashova L, et al.
32. LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN Özgüroğlu M, Goldman J, Reinmuth N, et al.
33. 100P Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer Marquez-Rodas I, Longo F, Aix S, et al.
34. 113P A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer Kotecki N, O'Neil B, Jalal S, et al.
35. 56P Predictive factors of intensive care outcomes of patients admitted with immune-related adverse events Paiva R, Cojocaru E, Grover V.
36. 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC) Hidalgo M, Semenisty V, Bockorny B, et al.
37. 46O Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated De Giglio A, Mezquita L, Auclin E, et al.
38. 51P Oncologists’ consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research Wilczynski O, Boisbouvier A, Radoszycki L, et al.
39. 20P The immune profiles in young, adult and elderly of advanced stage colorectal cancer patients Budhi I, Bagus M, Ayu S, et al.
40. LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042 Herbst R, Lopes G, Kowalski D, et al.
41. 131P PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours Juncker-Jensen A, Nagy M, Kuo J, et al.
42. 95O The immunoglobulin superfamily receptome defines cancer-relevant networks associated with response to immunotherapy Martinez-Martin N, Verschueren E, Husain B.
43. 129O Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 de Oliveira A, Madore J, O’donnell J, et al.
44. 44P Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy Fedorova L, Dubska L, Selingerova I, et al.
45. 138P Prognostic implications of residual disease tumour-infiltrating lymphocytes in gastric cancer patients after neoadjuvant chemotherapy Xing X, Jia S, Feng Y, et al.
46. 146P The dynamics between neo-adjuvant treatment and immune responses in human breast cancer Thomas N, Garaud S, De Wind A, et al.
47. 63P Influence of nivolumab on epidemiology of infectious complications in patients with relapse or refractory Hodgkin’s lymphoma Rogacheva Y, Popova M, Lepik K, et al.
48. 158P Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients Magri S, Pinton L, Masetto E, et al.
49. 79P Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer Enomoto T, Tamiya A, Matsumoto K, et al.
50. 111P Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors Moerk S, Donia M, Kringelum J, et al.
51. 62P Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma Beynarovich A, Lepik K, Mikhailova N, et al.
52. 128TiP VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial Jove M, Braña I, Taberna M, et al.
53. 10P Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC Mazzaschi G, Minari R, Ferri V, et al.
54. 112P Identification of a novel promiscuous anti-NY-ESO-1 immunogenic CD4+ peptide containing a CD8+ T-cell epitope highly present in metastatic gastric cancer responding to combined radiotherapy/anti-PD-1 immunotherapy Merhi M, Raza A, Inchakalody V, et al.
55. 61P Immunotherapy in patients with relapsed/refractory HIV-related lymphomas Popova M, Rogacheva Y, Tsygankov I, et al.
56. 87P Clinical outcomes of metastasic melanoma patients treated with ipilimumab and nivolumab: A single institution experience Oberoi H, Vila C, Rodriguez A, et al.
57. 150P Intratumoural MDSC recruitment by chemotherapeutic agent, 5-FU offsets the anti-tumor activity of immune-checkpoint inhibitor in HCC Kwong T, Wong C, Zhou J, et al.
58. 1O Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study Stenzinger A, Endris V, Budczies J, et al.
59. 120P Combination of triptorelin with nivolumab in ICI resistant advanced melanoma Robert C, Lejeune F, Lebbé C, et al.
60. 94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data Gao B, Goh J, Markman B, et al.
61. 76P Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) Staib J, Sudarsanam S, Byfield S, et al.
62. 18P The role of circulating neutrophils in the regulation of neoangiogenesis in ovarian cancer Abakumova T, Antoneeva I, Gening S, et al.
63. 119P Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma Tjulandin S, Fedyanin M, Demidov L, et al.
64. 145P Immune-competent 3D InSightTM tumour models as novel platform to assess combinatorial biologics therapy Chiovaro F, Buschmann N, Strebel S, et al.
65. 23P Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history Radosevic-Robin N, Reeves J, Leroy K, et al.
66. 156P T-cell and B-cell intratumoural interactions affect the progression of oropharyngeal squamous cell carcinoma Hladikova K, Koucky V, Boucek J, et al.
67. 118P The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model Krendyukov A, Kneisel N, Zhu J, et al.
68. 109P Phase I clinical study for validation of fimaporfin-based photochemical internalisation: A novel technology for enhancing cellular immune responses important for therapeutic effect of peptide-and protein-based vaccines Selbo P, Janetzki S, Welters M, et al.
69. 164P Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire Draghi A, Gokuldass A, Chamberlain C, et al.
70. 70P Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors de Miguel P, Gallego J, García I, et al.
71. 74P Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world Wang C, Gupte-Singh K, Belli A, et al.
72. 93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers Johnson M, Spira A, Carbone D, et al.
73. 133P Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty Berben L, Wildiers H, Kenis C, et al.
74. 34P Development of LAG-3 nanobodies as potent cancer imaging tracers Lecocq Q, Awad R, Zeven K, et al.
75. 98P Results from a phase I study of MK-1308 (anti–CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer Cho B, Yoh K, Bar J, et al.
76. 43P Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand Zafar S, Quixabeira D, Hemminki O, et al.
77. 148P NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches Papamichos S.
78. 86P A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC Viscardi G, Sparano F, Di Liello R, et al.
79. 97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti–PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) Rischin D, Khushalani N, Schmults C, et al.
80. 17P Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients Blanc-Durand F, Auclin E, Planchard D, et al.
81. 90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to standard chemotherapy (GORTEC 2018-03) Fayette J.
82. 144P Loss of BAP-1 influences the activation of p52 and RelB proteins in the Inflammatory microenvironment of uveal melanoma Singh M, Kashyap S, Singh L, et al.
83. 2O Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours Hollmén M, Virtakoivu R, Jaakkola P, et al.
84. 155P Interleukin 17F and vasculogenic mimicry: Potential therapeutic targets in oral tongue cancer? Almahmoudi R.
85. 88P A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea YI J.
86. 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours Reck M, Cappuzzo F, Rodriguez-Abreu D, et al.
87. 28P RNA-seq based transcriptome profiling provides important insights into progression of gastric cancer Verma R.
88. 108P Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances Th1 cytokine production Gavin M, Gragerov A, Espling E, et al.
89. 80P Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study Reck M, Syrigos K, Miliauskas S, et al.
90. 69P Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt) Hernando-Calvo A, Mirallas O, Marmolejo D, et al.
91. 40P Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine Tavartkiladze A, Khutsishvili R, Revazishvili P, et al.
92. 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817 Barlesi F, Audigier-Valette C, Felip E, et al.
93. 169P Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR) Anota A, Pozet A, Lefevre C, et al.
94. 33P Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice Lambin S, Lambrechts D, De Rop C, et al.
95. 27P Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI) Svedman F, Yang M, Tuominen R, et al.
96. 85P Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) Schmalz O, Jacob C, Ammann J, et al.
97. 11P PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer Patil R, Limaye S, Akolkar D, et al.
98. 143P Association of PTPRT mutation with survival of immune checkpoint inhibitor in patients with cancer Li A, Lin D, Yu Y, et al.
99. 104P A novel immunological role of hydrogen sulphide in shaping natural killer cells cytoxicity in breast cancer patients Youness R, Abdelmotaal A, Gad M.
100. 16P Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors Murthy N, Rauthan A, Patil P, et al.
更新于 10 分钟前

近期历史最近 100 条记录

2021-03-23 166P Insights in the mode of action of a T cell bispecific antibody in tumour bearing mice Giusti A, Sam J, Karagianni M, et al.
2021-03-23 78P A systematic review and meta-analysis of trials assessing activity of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for pre-treated advanced malignant mesothelioma (aMM) Tagliamento M, Bironzo P, De Luca E, et al.
2021-03-23 77P The characteristics of long-lasting responders to PD-1 inhibitor in advanced non-small cell lung cancer patients Jo H, Yoshida T, Yagishita S, et al.
2021-03-23 12P The expression of PD-1 alone by T cells is associated with cell activation while the co-expression of TIM-3 indicates exhausted subsets both in peripheral blood and bone marrow of multiple myeloma patients Batorov E, Sergeevicheva V, Aristova T, et al.
2021-03-23 151P Investigation of the mechanism of action of anti-PD-1 treatment by systematic depletion of different immune cell populations in syngeneic models Bourre L, Jin Y, Muntel J, et al.
2021-03-23 6P Prognostic significance of tumour-infiltrating lymphocytes on survival outcomes of patients with resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis Tan H, Catedral L, San Juan M.
2021-03-23 54P Applicability of the LIPI score to metastatic microsatellite instability high cancer patients treated with immune checkpoint inhibitors Vuagnat P, Auclin E, Mezquita L, et al.
2021-03-23 LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study Herbst R, de Marinis F, Giaccone G, et al.
2021-03-23 35O Phase I clinical trial of PD-1 knockout anti-MUC1 CAR-T cells in the treatment of patients with non-small cell lung cancer Lin Y, Chen S, Zhong S, et al.
2021-03-23 161P Regulatory interacting network between the immunomodulatory non-coding RNAs: miR-17-5p, MALAT1 and H19 lncRNAs in modulating the tumour microenvironment in TNBC Soliman R, Youness R, El-Shazly M, et al.
2021-03-23 47O Association of systemic corticosteroids with overall survival in patients receiving cancer immunotherapy for advanced melanoma, non-small cell lung cancer or urothelial cancer in routine clinical practice Drakaki A, Luhn P, Wakelee H, et al.
2021-03-23 48P A retrospective, observational study of telomerase peptide immunotherapy in heavily treated solid cancer patients Choi J.
2021-03-23 162TiP A phase I study evaluating BI 765063, a first in class selective myeloid SIRPa inhibitor, as standalone and in combination with BI 754091, a programmed death-1 (PD-1) inhibitor, in patients with advanced solid tumours Marabelle A, Cassier P, Delord J, et al.
2021-03-23 49P Thromboembolic risk assessment in patients receiving combination of anti-angiogenic plus anti-PD1 or anti-PD-L1: A descriptive study Bravo P, Vss B, Baldini C, et al.
2021-03-23 135P Analysis of the immune microenvironment in pre-treatment non-small cell lung cancer (NSCLC) patients with follow-up response data to second-line immunotherapy Bhagat M, Warren S, Elliott N, et al.
2021-03-23 LBA3 Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (aNSCLC): CheckMate 227 - part 2 final analysis Paz-Ares L, Ciuleanu T, Yu X, et al.
2021-03-23 7P Multispectral immunofluorescence and computational imaging analysis define the prognostic role of T-cell infiltrates in gastric cancer Challoner B, von Loga K, Woolston A, et al.
2021-03-23 160P Novel arginase inhibitor alone and in combination with an immune check point inhibitor reduces tumour growth in murine experimental gliomas Pilanc-kudlek P, Cyranowski S, Wojnicki K, et al.
2021-03-23 116P Development of advanced human immune system mouse models for pre-clinical research in immuno-oncology Mossu A, Tschumi B.
2021-03-23 130O Association of long non-coding RNA biomarkers with clinically immune subtype and prediction of immunotherapy in patients with cancer Yu Y, Zhang W, Li A, et al.
2021-03-23 96P Clearance of HPV anal premalignant lesions and modulation of systemic immune responses to HPV oncogenes with low dose pomalidomide Polizzotto M, Van Bockel D, Law C, et al.
2021-03-23 52P Chronic and late-onset toxicities from immune checkpoints inhibitors (ICIs): Analysis of the publications leading to ICIs approval between 2011 and 2019 Ghisoni E, Marandino L, Valabrega G, et al.
2021-03-23 123P Patient-Derived Explant Cultures (PDECs) as a model system for immuno-oncology studies Turpin R, Munne P, Suleymanova I, et al.
2021-03-23 LBA5 KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC Gadgeel S, Rodriguez-Abreu D, Felip E, et al.
2021-03-23 137P Comparative analysis of the immune microenvironment in histological subtypes of lung and breast cancer using a tissue microarray (TMA) comprising invasive margin (IM) and tumour centre (TC) Cumberbatch M, Memeo L, Womack C, et al.
2021-03-23 45P 5-AZA treatment induces cytotoxicity and in vitro expression of immunogenic NY-ESO-1 antigen in non-small lung cancer cell NCI-H1975 Inchakalody V, Taleb S, Sherif S, et al.
2021-03-23 39P TCR engaging antigen-scaffolds for targeted expansion of functionally improved T cells for adoptive cell therapy Kladis G, Mindahl V, Tamhane T, et al.
2021-03-23 147P A personalised approach for anti-GITR-based immunotherapy in pre-clinical models of pancreatic ductal adenocarcinoma Desai K, Ragulan C, Lawrence P, et al.
2021-03-23 102P Results from a phase II trial of pembrolizumab (P) plus gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 (PANGEA-Breast) study Merino L, Cruz J, Alonso J, et al.
2021-03-23 159P Supportive roles of microglia in breast cancer brain metastases Kaminska B, Wojnicki K, Kochalska A, et al.
2021-03-23 38P Obtaining tumour-specific T cells in a mouse melanoma model Yuzhakova D, Izosimova A, Barbashova L, et al.
2021-03-23 LBA2 First-line durvalumab plus platinum-etoposide in extensive-stage (ES)-SCLC: Safety, pharmacokinetics (PK) and immunogenicity in CASPIAN Özgüroğlu M, Goldman J, Reinmuth N, et al.
2021-03-23 100P Combination of intratumoural double-stranded RNA (dsRNA) BO-112 with systemic anti-PD-1 in patients with anti-PD-1 refractory cancer Marquez-Rodas I, Longo F, Aix S, et al.
2021-03-23 113P A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer Kotecki N, O'Neil B, Jalal S, et al.
2021-03-23 56P Predictive factors of intensive care outcomes of patients admitted with immune-related adverse events Paiva R, Cojocaru E, Grover V.
2021-03-23 91O A multi-center phase IIa trial to assess the safety and efficacy of BL-8040 (a CXCR4 inhibitor) in combination with pembrolizumab and chemotherapy in patients with metastatic pancreatic adenocarcinoma (PDAC) Hidalgo M, Semenisty V, Bockorny B, et al.
2021-03-23 46O Impact of early introduction of steroid on immune-checkpoint inhibitors (ICI) in patients with advanced non-small cell lung cancer treated De Giglio A, Mezquita L, Auclin E, et al.
2021-03-23 51P Oncologists’ consideration of health-related quality of life in clinical practice for immune-checkpoint inhibitors-treated patients: An online patients community research Wilczynski O, Boisbouvier A, Radoszycki L, et al.
2021-03-23 20P The immune profiles in young, adult and elderly of advanced stage colorectal cancer patients Budhi I, Bagus M, Ayu S, et al.
2021-03-23 LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in KEYNOTE-042 Herbst R, Lopes G, Kowalski D, et al.
2021-03-23 131P PD-1 and LAG-3 synergize to drive tumour-infiltration of T cytotoxic cells in NSCLC tumours Juncker-Jensen A, Nagy M, Kuo J, et al.
2021-03-23 95O The immunoglobulin superfamily receptome defines cancer-relevant networks associated with response to immunotherapy Martinez-Martin N, Verschueren E, Husain B.
2021-03-23 129O Resistance to immunotherapy is associated with high parenchymal PD1+CD8+/CD8+ T cells (PD1tR) driven by tumour CD155 de Oliveira A, Madore J, O’donnell J, et al.
2021-03-23 44P Evaluation of immune response in young patients with sarcoma treated by dendritic cell-based immunotherapy Fedorova L, Dubska L, Selingerova I, et al.
2021-03-23 138P Prognostic implications of residual disease tumour-infiltrating lymphocytes in gastric cancer patients after neoadjuvant chemotherapy Xing X, Jia S, Feng Y, et al.
2021-03-23 146P The dynamics between neo-adjuvant treatment and immune responses in human breast cancer Thomas N, Garaud S, De Wind A, et al.
2021-03-23 63P Influence of nivolumab on epidemiology of infectious complications in patients with relapse or refractory Hodgkin’s lymphoma Rogacheva Y, Popova M, Lepik K, et al.
2021-03-23 158P Role of iron metabolism in the immunosuppression mediated by myeloid cells in glioblastoma patients Magri S, Pinton L, Masetto E, et al.
2021-03-23 79P Nivolumab treatment beyond progression disease in advanced non-small cell lung cancer Enomoto T, Tamiya A, Matsumoto K, et al.
2021-03-23 111P Pilot study on the feasibility, safety and immunogenicity of a personalized neoantigen-targeted immunotherapy (NeoPepVac) in combination with anti-PD-1 or anti-PD-L1 in advanced solid tumors Moerk S, Donia M, Kringelum J, et al.
2021-03-23 62P Safety and efficacy of allogeneic stem cell transplantation after nivolumab therapy for patients with relapsed/refractory classical Hodgkin lymphoma Beynarovich A, Lepik K, Mikhailova N, et al.
2021-03-23 128TiP VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial Jove M, Braña I, Taberna M, et al.
2021-03-23 10P Genetic, tissue and circulating PD-L1 profiling to predict the response to immuno-checkpoint inhibitors in advanced NSCLC Mazzaschi G, Minari R, Ferri V, et al.
2021-03-23 112P Identification of a novel promiscuous anti-NY-ESO-1 immunogenic CD4+ peptide containing a CD8+ T-cell epitope highly present in metastatic gastric cancer responding to combined radiotherapy/anti-PD-1 immunotherapy Merhi M, Raza A, Inchakalody V, et al.
2021-03-23 61P Immunotherapy in patients with relapsed/refractory HIV-related lymphomas Popova M, Rogacheva Y, Tsygankov I, et al.
2021-03-23 87P Clinical outcomes of metastasic melanoma patients treated with ipilimumab and nivolumab: A single institution experience Oberoi H, Vila C, Rodriguez A, et al.
2021-03-23 150P Intratumoural MDSC recruitment by chemotherapeutic agent, 5-FU offsets the anti-tumor activity of immune-checkpoint inhibitor in HCC Kwong T, Wong C, Zhou J, et al.
2021-03-23 1O Harmonization and standardization of panel-based tumour mutational burden (TMB) measurement: Real-world results and recommendations of the QuIP study Stenzinger A, Endris V, Budczies J, et al.
2021-03-23 120P Combination of triptorelin with nivolumab in ICI resistant advanced melanoma Robert C, Lejeune F, Lebbé C, et al.
2021-03-23 94O Safety and antitumor activity of sitravatinib in combination with tislelizumab in patients with advanced solid tumors: Ovarian cancer cohort data Gao B, Goh J, Markman B, et al.
2021-03-23 76P Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC) Staib J, Sudarsanam S, Byfield S, et al.
2021-03-23 18P The role of circulating neutrophils in the regulation of neoangiogenesis in ovarian cancer Abakumova T, Antoneeva I, Gening S, et al.
2021-03-23 119P Final results of phase II trial (MIRACULUM) of the novel PD-1 inhibitor prolgolimab in patients with advanced melanoma Tjulandin S, Fedyanin M, Demidov L, et al.
2021-03-23 145P Immune-competent 3D InSightTM tumour models as novel platform to assess combinatorial biologics therapy Chiovaro F, Buschmann N, Strebel S, et al.
2021-03-23 23P Immunological signature meta-analysis across lung cancer cohorts within the NanoString Clinical Transcriptional Atlas Group (CTAG) associated with patient outcome and history Radosevic-Robin N, Reeves J, Leroy K, et al.
2021-03-23 156P T-cell and B-cell intratumoural interactions affect the progression of oropharyngeal squamous cell carcinoma Hladikova K, Koucky V, Boucek J, et al.
2021-03-23 118P The role of asunercept as a selective CD95L inhibitor in cutaneous melanoma: Rationale and results from an enhanced TiRP model Krendyukov A, Kneisel N, Zhu J, et al.
2021-03-23 109P Phase I clinical study for validation of fimaporfin-based photochemical internalisation: A novel technology for enhancing cellular immune responses important for therapeutic effect of peptide-and protein-based vaccines Selbo P, Janetzki S, Welters M, et al.
2021-03-23 164P Combined detection of CD137 and type 1 functions improves identification and characterization of the activated T lymphocyte repertoire Draghi A, Gokuldass A, Chamberlain C, et al.
2021-03-23 70P Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors de Miguel P, Gallego J, García I, et al.
2021-03-23 74P Cost of adverse events (AEs) with second-line (2L) immuno-oncology agents (IO) and chemotherapy (CHEMO) in advanced non-small cell lung cancer (aNSCLC) in the real-world Wang C, Gupte-Singh K, Belli A, et al.
2021-03-23 93O First results of phase I/II studies evaluating viral vector-based heterologous prime/boost immunotherapy against predicted HLA class I neoantigens demonstrate CD8 T cell responses in patients with advanced cancers Johnson M, Spira A, Carbone D, et al.
2021-03-23 133P Tumour immune infiltrate characterization in luminal breast cancer in three distinct age categories and its correlation with frailty Berben L, Wildiers H, Kenis C, et al.
2021-03-23 34P Development of LAG-3 nanobodies as potent cancer imaging tracers Lecocq Q, Awad R, Zeven K, et al.
2021-03-23 98P Results from a phase I study of MK-1308 (anti–CTLA-4) plus pembrolizumab in previously treated advanced small cell lung cancer Cho B, Yoh K, Bar J, et al.
2021-03-23 43P Enhancing the therapeutic effect of dendritic cell therapy by oncolytic adenovirus 3 encoding CD40-ligand Zafar S, Quixabeira D, Hemminki O, et al.
2021-03-23 148P NKG2E comprises an immunogenic peptide, derived from an alu-retrotransposon: An attractive novel target for immunotherapeutic approaches Papamichos S.
2021-03-23 86P A novel ImmunoScore, based on clinical and blood biomarkers, as prognostic model for immunotherapy in NSCLC Viscardi G, Sparano F, Di Liello R, et al.
2021-03-23 97P Impact of prior lines of systemic therapy (PST) on the efficacy of cemiplimab, a human monoclonal anti–PD-1, in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC) Rischin D, Khushalani N, Schmults C, et al.
2021-03-23 17P Association of lung immune prognostic index (LIPI) with survival of first line immune checkpoint inhibitors single agent or in combination with chemotherapy in untreated advanced NSCLC patients Blanc-Durand F, Auclin E, Planchard D, et al.
2021-03-23 90TiP FRAIL-IMMUNE: A multicenter, prospective, single arm phase II of the combination of durvalumab with carboplatin and paclitaxel as first-line treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck not eligible to Fayette J.
2021-03-23 144P Loss of BAP-1 influences the activation of p52 and RelB proteins in the Inflammatory microenvironment of uveal melanoma Singh M, Kashyap S, Singh L, et al.
2021-03-23 2O Biomarkers of immune switch induced by a novel anti-macrophage antibody (anti-Clever-1 mAb; FP-1305) in MATINS trial patients with advanced solid tumours Hollmén M, Virtakoivu R, Jaakkola P, et al.
2021-03-23 155P Interleukin 17F and vasculogenic mimicry: Potential therapeutic targets in oral tongue cancer? Almahmoudi R.
2021-03-23 88P A study on analysis of clinical efficacy factor and exploring prognostic factors for reimbursement policy after immunotherapy being introduced in South Korea YI J.
2021-03-23 127TiP PROPEL: A phase I/II trial of bempegaldesleukin (NKTR-214) in combination with pembrolizumab (pembro) in patients (pts) with advanced solid tumours Reck M, Cappuzzo F, Rodriguez-Abreu D, et al.
2021-03-23 28P RNA-seq based transcriptome profiling provides important insights into progression of gastric cancer Verma R.
2021-03-23 108P Phosphatidylserine suppresses T cells through GPR174, and co-inhibition of adenosine receptors and GPR174 synergistically enhances Th1 cytokine production Gavin M, Gragerov A, Espling E, et al.
2021-03-23 80P Nintedanib (N) + docetaxel (D) after immunotherapy in adenocarcinoma non-small cell lung cancer (NSCLC): First results from the non-interventional LUME-BioNIS study Reck M, Syrigos K, Miliauskas S, et al.
2021-03-23 69P Clinical biomarkers as predictors of immunotherapy (IT) benefit in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients (pt) Hernando-Calvo A, Mirallas O, Marmolejo D, et al.
2021-03-23 40P Treatment of refractory recurrent gastrointestinal stromal tumors with adoptive cellular immunotherapy (TILs) and personalized vaccine Tavartkiladze A, Khutsishvili R, Revazishvili P, et al.
2021-03-23 92O Nivolumab plus low-dose ipilimumab as first-line treatment of advanced NSCLC: Overall survival analysis of checkmate 817 Barlesi F, Audigier-Valette C, Felip E, et al.
2021-03-23 169P Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR) Anota A, Pozet A, Lefevre C, et al.
2021-03-23 33P Tumour mutational burden ring trial: Evaluation of targeted next-generation sequencing platforms for implementation in clinical practice Lambin S, Lambrechts D, De Rop C, et al.
2021-03-23 27P Single-nucleotide polymorphism variation (SNV): Possible candidates as predictive biomarkers to response and progression free survival (PFS) in cutaneous malignant melanoma (CMM) patients treated with immune checkpoint inhibitors (ICI) Svedman F, Yang M, Tuominen R, et al.
2021-03-23 85P Impact of digital patient monitoring (DPM) on quality of clinical care of cancer immunotherapy (CIT)-treated patients (pts) with advanced/metastatic non-small cell lung cancer (a/mNSCLC) Schmalz O, Jacob C, Ammann J, et al.
2021-03-23 11P PD-L1 profiling of circulating tumour cells is a viable companion diagnostic for checkpoint inhibitor therapy in lung cancer Patil R, Limaye S, Akolkar D, et al.
2021-03-23 143P Association of PTPRT mutation with survival of immune checkpoint inhibitor in patients with cancer Li A, Lin D, Yu Y, et al.
2021-03-23 104P A novel immunological role of hydrogen sulphide in shaping natural killer cells cytoxicity in breast cancer patients Youness R, Abdelmotaal A, Gad M.
2021-03-23 16P Neutrophil-lymphocyte ratio as a prognostic marker in a resource constraint setting for metastatic malignancies treated with immune checkpoint inhibitors Murthy N, Rauthan A, Patil P, et al.

匿名用户只展示最新 100 条榜单历史,更多历史数据请登录后查看,支持时光机按天筛选